Overview

To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris

Status:
Completed
Trial end date:
2018-01-26
Target enrollment:
Participant gender:
Summary
Bioequivalence study comparing Tretinoin Cream, 0.05% to RETIN-A®.
Phase:
Early Phase 1
Details
Lead Sponsor:
Taro Pharmaceuticals USA
Treatments:
Tretinoin